Novavax Announces Launch of Global Vaccine Education Programs
– ‘We Do Vaccines’ and ‘Know Our Vax’ are new educational efforts that provide information regarding vaccines – Programs explain
Read More– ‘We Do Vaccines’ and ‘Know Our Vax’ are new educational efforts that provide information regarding vaccines – Programs explain
Read More– NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection – High level of vaccine efficacy maintained over a 6-month period
Read More– PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population –
Read MoreNuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines
Read More– NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md.,
Read MoreGAITHERSBURG, Md. and PUNE, India, Dec. 28, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing
Read More– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants – Third dose produced
Read More– WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged
Read More– Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO – EUL for Nuvaxovid complements
Read MoreNuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European
Read More